[Recommendations for the management of latex allergy in pediatrics]

Karina A López,María P Sarraquigne,María E Gervasoni,Andrea I Mariño,Betina Menéndez Porfilio,Laura Sasia,Claudio A Agüero,Claudio A S Parisi,Mauricio D Colella,Ricardo J Saranz,Viviana Seisdedos,Ilse Behrens,Patricia L Dayan,Patricia Solari,Verónica Acosta,María Del P Bovina Martijena,Laura Del Pino,Martín Bózzola,Norberto Procopio,Fabio Orellano,Natalia L Luconi,Marcela C García,Cecilia Parente,Víctor Skrie,Julio Orellana,Alejandro Lozano,Grupo Editor Látex,Mónica L. Matta Rúffolo,María C. Cassaniti,Irene Aráoz,Jorge García,Héctor H. González,Antonio Sánchez Segovia,Aldo Cavallo,Gisella N. Solá
DOI: https://doi.org/10.5546/aap.2024-10431
2024-07-11
Abstract:Latex allergy, or natural rubber latex allergy (NRLA), is a global health concern, even among the pediatric population, with symptoms varying in severity from mild to potentially life-threatening. Latex is derived from the Hevea Brasiliensis tree, producing twelve million tons annually for use in various everyday and medical products. Despite efforts to mitigate NRLA, its prevalence remains high, especially in at- risk groups such as children with spina bifida. Clinical manifestations include immediate and delayed symptoms, even anaphylactic reactions. Diagnosis involves a detailed medical history and specific tests. Prevention focuses on avoiding exposure, especially in medical and educational settings. Treatment, including immunotherapy, exhibits variable efficacy. NRLA has a strong negative impact on children's quality of life. The objective of this publication is to provide updated information and practical tools for the pediatrician's and allergist's practice.
What problem does this paper attempt to address?